SAFI BIOTHERAPEUTICS received a $4.7 million deferred grant from the US Department of Defense Advanced Research Projects Agency to advance the first clinical trial of artificial red blood cells.

Zhitongcaijing · 11/03 13:09
SAFI BIOTHERAPEUTICS received a $4.7 million deferred grant from the US Department of Defense Advanced Research Projects Agency to advance the first clinical trial of artificial red blood cells.